6,210 Patients Enrolled for Solid Tumors, Advanced Solid Tumors
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
Participants expected to have received the same standard of care therapies as other people with cancer, including an available PD-(L)1 inhibitor if their Eastern cooperative oncology group performance status was 0 or 1.
People with advanced squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), or renal cell cancer (RCC) that has spread (metastasized) and cannot be surgically removed, are eligible to participate in this study
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.